Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients

• Status: Unknown status
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypertensive patients with moderate hypertension have a risk to develop cardiovascular events of 15-20% over a period of 10 years. It is important to reach quickly the advised target, but often this result can be obtained with a combination therapy. Some evidences demonstrate sartans and calcium channels blockers can be very useful and safe, but it is also important to verify which association can give side effects or give some pharmacokinetic interactions that can negatively influence the clinical combination efficacy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pavia
• Treatments: Amlodipine; Amlodipine, Valsartan Drug Combination; Losartan; Valsartan

Criteria

Inclusion Criteria:

• diastolic blood pressure in sitting position 100 to 109 mmHg and systolic blood pressure > 140 mmHg at the end of the selection period

Exclusion Criteria:

• type 2 diabetes mellitus

• heart failure

• AMI in the previous 6 months

• angina pectoris

• secondary hypertension

• malignant hypertension

• women child-bearing potential

• women who are pregnant and lactating

• suspected history of allergy to the sartans or calcium channels blockers